The interim results of the phase IIb trial showed that after subcutaneous injection of monoclonal antibody ASC22 treatment, persistent hepatitis B surface antigen disappearance was observed in patients with chronic hepatitis B

- Evaluate the disappearance of hepatitis B surface antigen in 44 patients who completed 24 weeks of treatment with 1 mg/kg ASC22 (n=33) or placebo (n=11) combined with nucleoside (acid) analogs

- Of the 33 patients treated with ASC22, 16 had hepatitis B surface antigen ≤ 500 IU/mL at baseline, and 19% (3/16) of the patients achieved hepatitis B surface antigen disappearance after ASC22 treatment, and after ASC22 was discontinued There was no rebound, indicating a functional cure for hepatitis B

Hangzhou and Shaoxing, China, November 9th, 2021/PRNewswire/ - Golly Pharmaceuticals Co.

The Phase IIb trial is a randomized, single-blind, placebo-controlled, multi-center Chinese clinical trial to evaluate 1 mg/kg, 2.

"ASC22 is the world's earliest and fastest-growing clinical study for functional cure of hepatitis B (ie, the disappearance of hepatitis B surface antigen) by blocking the PD-1/PD-L1 signaling pathway.

"Scientists all over the world are making unremitting efforts to cure hepatitis B, but the disappearance of hepatitis B antigen is difficult to achieve

The summary information of the report is as follows:

HBsAg LOSS IN CHRONIC HEPATITIS B PATIENTS WITH SUBCUTANEOUS PD-L1 ANTIBODY ASC22 (ENVAFOLIMAB) PLUS NUCLEOS(T)IDE ANALOGS TREATMENT: INTERIM RESULTS FROM A PHASE IIb CLINICAL TRIAL

Report format: Parallel session, oral report abstract number: LO12 Conference theme: latest abstract Session 2 Speaker: Dr.

About songli

Gale is an innovative R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.

1.

Source: Golly Pharmaceutical Co.